THE BEST SIDE OF ABBV-744 CLINICAL TRIAL PHASE 2 DATA

In Section C, participants will get ABBV-744 and oral navitoclax. In Segment D, individuals will acquire ABBV-744 and ruxolitinib. Participants will obtain treatment right until disorder progression or the members are unable to tolerate the study drugs.There might be greater treatment load for participants With this trial when compared with their c